This brand name is authorized in Australia, Austria, Finland, Hong Kong SAR China, Netherlands, New Zealand, Poland, UK.
The drug RESONIUM contains one active pharmaceutical ingredient (API):
1
|
UNII
1699G8679Z - SODIUM POLYSTYRENE SULFONATE
|
Below package inserts are available for further reading:
| Document | Type | Information Source | |
|---|---|---|---|
| RESONIUM A Powder | MPI, EU: SmPC | Medicines & Healthcare Products Regulatory Agency (GB) |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC Group | Classification | |
|---|---|---|
| V03AE01 | Polystyrene sulfonate | V Various → V03 All other therapeutic products → V03A All other therapeutic products → V03AE Drugs for treatment of hyperkalemia and hyperphosphatemia |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| AU | Pharmaceutical Benefits Scheme | 4470G |
| FI | Lääkealan turvallisuus- ja kehittämiskeskus | 163709 |
| GB | Medicines & Healthcare Products Regulatory Agency | 41068 |
| HK | Department of Health Drug Office | 42418 |
| NL | Z-Index G-Standaard | 13650203 |
| NL | Z-Index G-Standaard, PRK | 130656 |
| NZ | Medicines and Medical Devices Safety Authority | 2958 |
| PL | Rejestru Produktów Leczniczych | 100057994 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.